Parasites & vectors · 2025
PD-1-dependent therapeutic effect of Trichinella spiralis cystatin on myocardial infarction in a mice model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Weixiao, Yin Wenhui, Wang Hongtao, Wu Lingqin, Li Chang, Peng Xinyu, Li Xiang, Jiang Kaibo, Yang Huiqi, Dang Chenyue, Gao Erhe, Jin Qiwang, Yang Xiaodi
Аннотация
BACKGROUND: Ischemia-induced inflammation is the primary pathological mechanism underlying cardiac tissue injury caused by myocardial infarction (MI). Trichinella spiralis cystatin (Ts-Cys) has been shown to regulate macrophage polarization and alleviate various inflammatory and immune-related diseases. Programmed cell death-1 (PD-1) is a crucial checkpoint receptor molecule and highly involved in maintaining immune tolerance. In this study, our aims were to investigate whether recombinant Ts-Cys protein (rTs-Cys) could be used to treat MI with recruited macrophage-dominant myocardial inflammation and whether PD-1 is involved in the immunomodulation of Ts-Cys in inflammatory diseases.
METHODS: MI models were established in wild-type (WT) and PD-1 knockout (PD-1-/-) mice, followed by the intraperitoneal injection of rTs-Cys. The survival rates of mice were observed for 28 days post-surgery and treatment. Cardiac function was assessed by echocardiography. Histopathological evaluation of heart tissue affected by infarction was conducted to examine local inflammatory cell infiltration and cardiac tissue damage. Real-time quantitative PCR was used to detect messenger RNA expression levels of vascular endothelial growth factor (VEGF) and the macrophage surface markers inducible nitric oxide synthase and arginase-1 in the MI area. Serological levels of cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), were measured using an enzyme-linked immunosorbent assay. Bone marrow-derived macrophages from WT and PD-1-/- mice were used to assess the effects of rTs-Cys on macrophage polarization in vitro.
RESULTS: In WT mice, rTs-Cys treatment significantly improved the 28-day survival rate and cardiac function, reduced local inflammatory cell infiltration and cardiac pathological damage and increased VEGF expression levels of MI mice. The therapeutic effect of rTs-Cys was associated with macrophage polarization from the pro-inflammatory M1 phenotype to the regulatory M2 phenotype with reduced levels of inflammatory cytokines (TNF-α and IL-6) and increased levels of regulatory cytokines (IL-10 and TGF-β), as determined by both in vivo and in vitro tests. However, this therapeutic effect of rTs-Cys on MI was significantly reduced in PD-1-/- mice, as reflected by the higher level of M1 macrophages, elevated levels of inflammatory cytokines and decreased levels of regulatory cytokines.
CONCLUSIONS: rTs-Cys promotes M2-type polarization of macrophages through the PD-1 pathway to alleviate MI in mice and is, therefore, a potential drug for the treatment of MI and other inflammation-related diseases with involvement of the PD-1 checkpoint molecule.
METHODS: MI models were established in wild-type (WT) and PD-1 knockout (PD-1-/-) mice, followed by the intraperitoneal injection of rTs-Cys. The survival rates of mice were observed for 28 days post-surgery and treatment. Cardiac function was assessed by echocardiography. Histopathological evaluation of heart tissue affected by infarction was conducted to examine local inflammatory cell infiltration and cardiac tissue damage. Real-time quantitative PCR was used to detect messenger RNA expression levels of vascular endothelial growth factor (VEGF) and the macrophage surface markers inducible nitric oxide synthase and arginase-1 in the MI area. Serological levels of cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), were measured using an enzyme-linked immunosorbent assay. Bone marrow-derived macrophages from WT and PD-1-/- mice were used to assess the effects of rTs-Cys on macrophage polarization in vitro.
RESULTS: In WT mice, rTs-Cys treatment significantly improved the 28-day survival rate and cardiac function, reduced local inflammatory cell infiltration and cardiac pathological damage and increased VEGF expression levels of MI mice. The therapeutic effect of rTs-Cys was associated with macrophage polarization from the pro-inflammatory M1 phenotype to the regulatory M2 phenotype with reduced levels of inflammatory cytokines (TNF-α and IL-6) and increased levels of regulatory cytokines (IL-10 and TGF-β), as determined by both in vivo and in vitro tests. However, this therapeutic effect of rTs-Cys on MI was significantly reduced in PD-1-/- mice, as reflected by the higher level of M1 macrophages, elevated levels of inflammatory cytokines and decreased levels of regulatory cytokines.
CONCLUSIONS: rTs-Cys promotes M2-type polarization of macrophages through the PD-1 pathway to alleviate MI in mice and is, therefore, a potential drug for the treatment of MI and other inflammation-related diseases with involvement of the PD-1 checkpoint molecule.